Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2103 in Advanced Malignant Tumors
NCT05867563Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2103 in malignant neoplasm, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Status: unknown.
02
Drugs
TQB2103
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT05867563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867563.